Cipla Limited

Cipla reported its highest-ever Q1 revenue of INR 7,119 crores, marking a 2% year-on-year growth. On an adjusted basis, accounting for a change in financial presentation primarily in South Africa, the growth would be approximately 4%. This strong start to the fiscal year reinforces the company's business fundamentals and diversified portfolio, strengthening confidence in sustaining long-term growth.

The 'One India' business achieved its highest-ever quarterly revenue with a 12% year-on-year growth, reflecting strong performance across key therapies. The branded prescription segment demonstrated significant momentum, growing 15.4% as per IQVIA data, with the overall chronic mix strengthening to 60.4% year-on-year. Key therapies like Respiratory, Anti-diabetes, Cardiac, and Urology all registered strong double-digit growth, driven by volume expansion and new product launches.

North America generated $162 million in revenue, with Cipla maintaining its #1 position in the overall U.S. Albuterol MDI market with a 21% share. A key highlight was the successful launch of generic Ventolin, with commercial shipments commencing and volumes expected to increase towards the end of the financial year. The company anticipates continued sequential growth, supported by upcoming launches including three significant respiratory assets and one large peptide product, aiming for a $1 billion exit run rate for FY27.

The reported EBITDA margin stood at 16.7% for the quarter, impacted by higher-than-normal inventory write-offs and war-related costs, estimated at 1-2% of revenue. Management acknowledged that the current margin level is below its steady state, primarily due to investments in new product launches and facility readiness. However, they reiterated the FY27 EBITDA margin guidance of 18.5% to 20%, expecting gradual sequential improvement in coming quarters driven by new products, facility utilization, and cost optimization.

On the regulatory front, Cipla received a VAI classification for its Verna, Goa facility after a routine GMP inspection. The Invagen facility in New York received one Form 483 observation, which the company is committed to addressing within the stipulated timeline. In South Africa, the business experienced a decline in tender revenue due to a lost tender from the previous year, with this impact expected to continue in subsequent quarters, although the private market grew healthily at 6.5%.

The company reported a healthy net cash equivalent balance of INR 9,494 crores as of June 30, 2026, after a dividend payment of INR 1,050 crores. Gross debt, including lease liabilities, stood at INR 600 crores. R&D investments for the quarter were INR 486 crores, or 6.8% of revenue, primarily directed towards product filings and key development programs. Cipla continues to explore M&A opportunities for differentiated products in the US and Europe, while focusing on organic growth through increased capex and internal pipeline assets.